Antibacterial Wound Dressing With Rapid Clot-Promoting Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound dressings with antibiotics and silver ions are toxic to bacteria but also cytotoxic to mammalian cells, and they fail to effectively promote clot formation and inhibit infection at the wound site.
Innovation Solution
A wound dressing comprising a resinous matrix with propolis, tranexamic acid (TXA), and a nitric oxide donor (e.g., S-nitroso-N-acetylpenicillamine, SNAP), integrated with a biocompatible polymer like CarboSil®, promotes rapid clot formation and antimicrobial properties without cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics and silver ions are used in wound dressings, then antibacterial effect is improved, but cytotoxicity to mammalian cells increases
Solution Approach 1:
The patent removes harmful antibacterial agents (antibiotics and silver ions) from the wound dressing and replaces them with a benign alternative (tranexamic acid) that achieves antibacterial效果 through clot formation rather than direct bacterial killing, thereby eliminating cytotoxicity while maintaining antibacterial efficacy
Solution Approach 2:
The patent introduces clot formation as an intermediary mechanism that indirectly achieves antibacterial effect. Tranexamic acid promotes fibrin clot formation, which physically blocks bacterial access to the wound site and creates a barrier that prevents infection, rather than directly killing bacteria with toxic substances
2Reliability
If conventional wound dressings are used, then antibacterial properties are provided, but clot formation promotion is insufficient
Solution Approach 1:
The patent makes tranexamic acid serve multiple functions simultaneously: it acts as an antifibrinolytic agent to stabilize existing clots, promotes rapid clot formation through fibrinogen conversion, and creates a physical barrier against bacterial invasion, thereby combining hemostatic and antibacterial functions in a single agent
Solution Approach 2:
The patent applies tranexamic acid topically to the wound site before significant blood loss or infection can occur, enabling preemptive clot formation that seals the wound and prevents bacterial colonization before they become problematic
3Speed
If rapid clot formation is achieved, then hemorrhage control is improved, but antibacterial protection may be compromised
Solution Approach 1:
The patent converts the potential harm of rapid clot formation (which might trap bacteria within the clot) into a benefit by creating a dense fibrin barrier that physically isolates and traps bacteria within the clot structure, preventing their spread to surrounding tissues while maintaining the integrity of the wound barrier
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dressing achieves nearly instant clot formation and a 99.3% reduction in bacterial colonization, extending the critical time window for effective wound treatment before hospitalization, while being non-toxic to mammalian cells.
Implementation Method 1
the dressing promotes fibrin formation, rapid platelet aggregation, and has antimicrobial properties without being cytotoxic
Implementation Method 2
a nitric oxide donor (e.g., S-nitroso-N-acetylpenicillamine, SNAP)
Data Source
AI summary
Wound dressings and methods for treating a wound are provided. The wound dressing can have an environment-facing side that includes a biocompatible material having a polymer crosslinked with an antimicrobial effective amount of a NO-donor and a woundfacing side including a biocompatible resinous matrix and an antifibrinolytic agent. The wound dressing can promote fibrin formation and rapid platelet aggregation, and has antimicrobial properties. The dressing can be applied directly to the wound.